Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 161 to 170 of 2450 total matches.
Ophthalmic Ciprofloxacin
The Medical Letter on Drugs and Therapeutics • May 31, 1991 (Issue 845)
Chemother, 33:593, 1989; M
Trucksis et al, Ann Intern Med, 114:424, March 1, 1991). Resistance ...
An ophthalmic formulation of ciprofloxacin hydrochloride (Ciloxan - Alcon), a fluoroquinolone antibiotic, was recently marketed in the USA for treatment of bacterial keratitis and conjunctivitis. Ciprofloxacin has been used orally (Cipro) to treat a variety of serious infections (Medical Letter, 30:11, 1988) and recently was approved for intravenous administration.
Polidocanol (Varithena) for Varicose Veins
The Medical Letter on Drugs and Therapeutics • Aug 03, 2015 (Issue 1474)
and stripping.1
A meta-analysis of 13 randomized controlled
trials in ˃3000 patients with great saphenous ...
An injectable foam formulation of the sclerosing
agent polidocanol (Varithena – Provensis/BTG)
has been approved by the FDA for treatment of
incompetent veins and visible varicosities of the great
saphenous vein system. It is the first foam therapy to
be approved for this indication, but polidocanol and
other sclerosants have been used for years as foam
formulations compounded by physicians. Polidocanol
is also available in a liquid formulation (Asclera)
to treat smaller veins. Sodium tetradecyl sulfate
(Sotradecol) is FDA-approved in a liquid formulation
for use in...
Drugs for Menopausal Symptoms
The Medical Letter on Drugs and Therapeutics • Mar 04, 2024 (Issue 1697)
is the most effective treatment for GSM.1 When OTC
nonhormonal products are ineffective, low-dose
vaginal ...
The primary symptoms of menopause are genitourinary
and vasomotor. The genitourinary syndrome
of menopause (GSM) includes symptoms such as
burning, irritation, dryness, dyspareunia, dysuria,
and recurrent urinary tract infection. Vasomotor
symptoms (VMS; hot flashes, night sweats) often
disrupt sleep.
Med Lett Drugs Ther. 2024 Mar 4;66(1697):33-8 doi:10.58347/tml.2024.1697a | Show Introduction Hide Introduction
Nisoldipine-A New Calcium-Channel Blocker for Hypertension
The Medical Letter on Drugs and Therapeutics • Feb 16, 1996 (Issue 968)
).
CALCIUM-CHANNEL BLOCKERS FOR HYPERTENSION
Drug Daily adult dosage Cost
1
Frequent or severe adverse ...
Nisoldipine (Sular -Zeneca), a dihydropyridine calcium-channel blocker structurally similar to nifedipine, has been approved for marketing by the US Food and Drug Administration. It is available in an oral extended-release formulation for treatment of hypertension.
Lispro, A Rapid-Onset Insulin
The Medical Letter on Drugs and Therapeutics • Oct 25, 1996 (Issue 986)
levels that reach a peak in 1 ⁄
1
2 to 2 hours and remain elevated for 5 to 12
hours; serum glucose ...
Lispro insulin (Humalog - Lilly), a synthetic insulin analog, has been approved for marketing by the US Food and Drug Administration. Prepared by recombinant DNA methods using E. coli, lispro differs from human insulin in having lysine and proline at positions 28 and 29 on the beta-chain, reversed from their natural position. The new drug has biologic effects similar to unmodified insulin, but is absorbed more rapidly after subcutaneous injection.
An EUA for Baricitinib (Olumiant) for COVID-19
The Medical Letter on Drugs and Therapeutics • Dec 28, 2020 (Issue 1614)
in combination with the IV antiviral drug remdesivir
(Veklury).1 Baricitinib has been available for treatment ...
The oral Janus kinase (JAK) inhibitor baricitinib
(Olumiant – Lilly) has been granted an FDA Emergency
Use Authorization (EUA) for treatment of confirmed or
suspected COVID-19 in hospitalized patients ≥2 years
old who require supplemental oxygen, mechanical
ventilation, or extracorporeal membrane oxygenation
(ECMO); the EUA requires that baricitinib be used
in combination with the IV antiviral drug remdesivir
(Veklury). Baricitinib has been available for treatment
of rheumatoid arthritis since 2018. Remdesivir was
recently approved by the FDA for treatment of COVID-19
in...
COVID-19 Update: Bivalent Pfizer and Moderna COVID-19 Vaccines for Booster Immunization
The Medical Letter on Drugs and Therapeutics • Oct 03, 2022 (Issue 1660)
in persons ≥12 years old.1
THE NEW FORMULATIONS – The bivalent vaccine
formulations contain equal amounts ...
The FDA has amended its Emergency Use Authorizations
(EUAs) for the mRNA COVID-19 vaccines
manufactured by Pfizer/BioNTech (Comirnaty)
and Moderna (Spikevax) to permit use of bivalent
formulations of the products as a single booster dose
in persons ≥12 years old (Pfizer) or ≥18 years old
(Moderna) whose most recent COVID-19 vaccine dose
was a monovalent product given ≥2 months previously
as a booster or for completion of a primary series. The
bivalent formulations are not authorized for primary
immunization. Monovalent Pfizer and Moderna
COVID-19 vaccines are no longer...
In Brief: Empagliflozin (Jardiance) for Chronic Kidney Disease
The Medical Letter on Drugs and Therapeutics • Nov 13, 2023 (Issue 1689)
to improve renal outcomes (see
Table 1). The SGLT2 inhibitors ertugliflozin (Steglatro)
and bexagliflozin ...
The sodium-glucose cotransporter 2 (SGLT2) inhibitor
empagliflozin (Jardiance – Boehringer Ingelheim/Lilly) is now FDA-approved to reduce the risk of
sustained eGFR decline, end-stage kidney disease,
cardiovascular death, and hospitalization in adults with
chronic kidney disease (CKD) at risk of progression.
It is also approved to improve glycemic control in
patients ≥10 years old with type 2 diabetes, to reduce
the risk of cardiovascular death and hospitalization
for heart failure (HF) in adults with HF, and to reduce
the risk of cardiovascular death in adults with type...
Med Lett Drugs Ther. 2023 Nov 13;65(1689):183-4 doi:10.58347/tml.2023.1689c | Show Introduction Hide Introduction
Three New Oral Contraceptives
The Medical Letter on Drugs and Therapeutics • Sep 25, 2006 (Issue 1244)
production more effectively than those with the traditional 7-day interval.
1
SEASONIQUE — As with its ...
Three new combination oral contraceptives (COCs) with shortened hormone-free intervals, Seasonique, Loestrin 24 Fe and Yaz, have recently been approved by the FDA. All 3 are derivatives of older products.
Netupitant/Palonosetron (Akynzeo) for Chemotherapy-Induced Nausea and Vomiting
The Medical Letter on Drugs and Therapeutics • Apr 27, 2015 (Issue 1467)
(Helsinn/Eisai), an oral
fixed-dose combination of the substance P/neurokinin
1 (NK1) receptor antagonist ...
The FDA has approved Akynzeo (Helsinn/Eisai), an oral
fixed-dose combination of the substance P/neurokinin
1 (NK1) receptor antagonist netupitant and the
serotonin-3 (5-HT3) receptor antagonist palonosetron,
for prevention of acute and delayed nausea and
vomiting associated with cancer chemotherapy
in adults. Akynzeo is the first product to combine
drugs from these two classes. Palonosetron (Aloxi)
is also available as a single agent for prevention of
chemotherapy-induced and postoperative nausea
and vomiting. Netupitant is the second substance
P/NK1 receptor antagonist to be...